Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Solid Neoplasms With NTRK Fusions”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 0 results

Early research (Phase 1)Study completedNCT02675491
What this trial is testing

Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors

Who this might be right for
Advanced Solid Malignant Tumors
Daiichi Sankyo Co., Ltd. 15
Not applicableLooking for participantsNCT04142437
What this trial is testing

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

Who this might be right for
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Bayer 150
Early research (Phase 1)Study completedNCT02122913
What this trial is testing

Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer 75
Not applicableNo Longer AvailableNCT03206931
What this trial is testing

Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer
Testing effectiveness (Phase 2)Study completedNCT02576431
What this trial is testing

Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer 215
Testing effectiveness (Phase 2)Active Not RecruitingNCT02568267
What this trial is testing

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Who this might be right for
Breast CancerCholangiocarcinomaColorectal Cancer+13 more
Hoffmann-La Roche 534
Not applicableStudy completedNCT06837090
What this trial is testing

Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK)

Who this might be right for
Solid Neoplasms With NTRK Fusions
Grupo Espanol de Tumores Neuroendocrinos 20
Early research (Phase 1)Study completedNCT03215511
What this trial is testing

Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

Who this might be right for
Solid Tumors Harboring NTRK Fusion
Bayer 81
Testing effectiveness (Phase 2)Looking for participantsNCT06010342
What this trial is testing

Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

Who this might be right for
Solid Tumor
Teligene US 60
Not applicableStudy completedNCT04010240
What this trial is testing

A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study

Who this might be right for
Metastatic Solid Tumors
Institut Bergonié 3,820
Early research (Phase 1)UnknownNCT04671849
What this trial is testing

An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.

Who this might be right for
Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion
Jiangsu Simcere Pharmaceutical Co., Ltd. 243